References
- Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858–871.
- Chyka PA, Conner HG. Availability of antidotes in rural and urban hospitals in Tennessee. Am J Hosp Pharm. 1994;51:1346–1348.
- Dart RC, Stark Y, Fulton B, et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. JAMA. 1996;276:1508–1510.
- Woolf AD, Chrisanthus K. On-site availability of selected antidotes: results of a survey of Massachusetts hospitals. Am J Emerg Med. 1997;15:62–66.
- Hoffman RS. Antidote shortages in the United States: impact and response. Clin Toxicol. 2014;52:157–159.
- Howland MA, Weisman R, Sauter D, et al. Nonavailability of poison antidotes. N Engl J Med. 1986;314:927–928.
- Marraffa JM, Cohen V, Howland MA. Antidotes for toxicological emergencies: a practical review. Am J Health Syst Pharm. 2012;69:199–212.
- Dart RC, Borron SW, Caravati EM, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2009;54:386–394 e1.
- RED BOOK ONLINE® [database on the Internet]. Ann Arbor (MI): Truven Health Analytics; 2015 [cited 2015 Jun 1]. Available from: www.micromedexsolutions.com. Subscription required to view.
- Bureau of Labor and Statistics [Internet]. Consumer price index. Washington (DC): United States Department of Labor; 2015 [cited 2015 Jun 1]. Available from: http://www.bls.gov/cpi/
- Willingham E. Why did Mylan hike EpiPen prices 400%? Because they could. Forbes [Internet]. 2016 [cited 2016 Oct 24]. Pharma & Healthcare: [about 3 screens]. Available from: http://www.forbes.com/sites/emilywillingham/2016/08/21/why-did-mylan-hike-epipen-prices-400-because-they-could/#34253ad4477a
- Rockoff JD, Silverman E. Pharmaceutical companies buy rivals’ drugs, then jack up the prices. The Wall Street Journal [Internet]. 2015 [cited 2016 Oct 24]; Business: [about 4 screens]. Available from: http://www.wsj.com/articles/pharmaceutical-companies-buy-rivals-drugs-then-jack-up-the-prices-1430096431
- Fox ER, Tyler LS. Potential association between drug shortages and high-cost medications. Pharmacotherapy. 2017;37:36–42.
- Mazer-Amirshahi M, Hawley KL, Zocchi M, et al. Drug shortages: implications for medical toxicology. Clin Toxicol. 2015;53:519–524.
- Winger BJ, Clements EA, DeYoung JL, et al. Cost savings from dose rounding of biologic anticancer agents in adults. J Oncol Pharm Pract. 2011;17:246–251.
- Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–656.
- Nordt SP, Clark RF, Machado C, et al. Assessment of digoxin-specific fab fragment dosages in digoxin poisoning. Am J Ther. 2016;23:e63–e67.
- Allen RJ. Consignment purchasing saves money, improves cash flow, streamlines material management function. Hosp Top. 1985;63:28–29.
- Sjoerdsma M. Consignment offers hospitals cost benefits. Hosp Mater Manage. 1990;15:19.
- Amazing stories. BioCare [Internet]. 2017 [cited 2017 Jan 11]. About: [about 2 screens]. Available from: http://biocare-us.org/stories/
- Sivilotti ML, Eisen JS, Lee JS, et al. Can emergency departments not afford to carry essential antidotes? CJEM. 2002;4:23–33.
- Thurtle N, Greig J, Cooney L, et al. Description of 3180 courses of chelation with dimercaptosuccinic acid in children <5 y with severe lead poisoning in Zamfara, Northern Nigeria: a retrospective analysis of programme data. PLoS Med. 2014;11:1–18.
- Narra A, Lie E, Hall M, et al. Resource utilization of pediatric patients exposed to venom. Hosp Pediatr. 2014;4:276–282.
- Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52:824–836.